AACR 2012

 
 
 

The AACR Annual Meeting 2012 took place March 31-April 4 in Chicago, Illinois.

Photo courtesy of AACR; Credit: Todd Buchanan.

 

Investigators solve mystery of demethylating agents

HT Staff Read Article
Published: 04/09/12

AACR_2012_attendees_credit_AACR_230.jpg
AACR Annual Meeting 2012
Credit: AACR/Todd Buchanan

In an attempt to improve therapy with 2 demethylating agents, researchers went back to the drawing board and gained new insight into how the drugs function. The agents—azacitidine and decitabine—have proven effective when given in low doses to patients with myelodysplastic syndrome (MDS). But researchers have also observed a prolonged time to response in these patients, and they wanted to know why. “[W]e saw results in clinical trials that made us go back to the laboratory . . . [Read Article]

Imaging technique could speed cancer detection

HT Staff Read Article
Published: 04/09/12

AACR_crowd_Credit_Phil_McCarten_220.jpg
Session attendees at the
AACR Annual Meeting 2012
Credit: AACR/Phil McCarten

A new imaging technique relies on light and sound to create detailed, color pictures of tumors deep inside the body. The technology, called photoacoustic tomography (PAT), may eventually help physicians diagnose cancer earlier and more precisely monitor the effects of cancer treatment, according to Lihong V. Wang, PhD, of Washington University in St. Louis, Missouri. Dr Wang described PAT imaging at the AACR Annual Meeting 2012 and in a paper recently published in Science. [Read Article]

Drug can fight DLBCL with minimal toxicity

HT Staff Read Article
Published: 04/07/12

Staudt_Louis_Credit_AACR_Phil_McCarten_230.jpg
Louis Staudt, MD, PhD
Credit: AACR/Phil McCarten

Preliminary results of 2 small trials indicate the drug ibrutinib elicits significant responses—without significant toxicity—in patients with aggressive diffuse large B-cell lymphoma (DLBCL), regardless of disease subtype. Previous research has shown that ibrutinib potently and irreversibly inhibits Bruton’s tyrosine kinase (BTK). This kinase is a critical element of the NFkappaB pathway, which is activated by B-cell receptor (BCR) signaling in the activated B-cell (ABC) subtype of DLBCL. So investigators . . . [Read Article]

DLBCL risk greatly increased for solid organ recipients

HT Staff Read Article
Published: 04/05/12

AACR_2012_attendees_credit_AACR_230.jpg
AACR Annual Meeting 2012
Credit: AACR/Todd Buchanan

Recipients of solid organ transplants are at an increased risk of developing diffuse large B-cell lymphoma (DLBCL), according to new research presented at the AACR Annual Meeting 2012. Researchers found that, although the kidney was the most frequently transplanted organ in the cohort studied, the incidence ratio for DLBCL was highest for patients who received lung, pancreas, or kidney-pancreas transplants. Todd M. Gibson, PhD, of the National Cancer Institute, and his colleagues . . . [Read Article]

Team says cancer patients need more comprehensive care

HT Staff Read Article
Published: 04/05/12

AACR_2012_crowd_session_Phil_McCarten_230.jpg
Session at AACR Annual Meeting
Credit: AACR/Phil McCarten

Disease recurrence is the overriding fear for many cancer survivors. But in a new study, nearly half of survivors ultimately died from conditions other than cancer. These results indicate survivors could potentially benefit from a more comprehensive, less cancer-focused approach to their health, according to lead researcher Yi Ning, MD, ScD, of Virginia Commonwealth University. Dr Ning presented these results at the AACR Annual Meeting 2012 as abstract LB-339. [Read Article]

IAP inhibitor effective in some lymphomas

HT Staff Read Article
Published: 04/04/12

AACR_meeting_poster_session_Photo_by_AACR-Scott_Morgan_230.jpg
Poster session at AACR 2012
Credit: AACR/Scott Morgan

A novel agent targeting inhibitor of apoptosis proteins (IAPs) shows promise for treating certain types of lymphoma, according to data presented at the AACR Annual Meeting 2012. The agent, TL32711, induced apoptosis in cell lines of follicular lymphoma (FL) and germinal center diffuse large B-cell lymphoma (GC DLBCL). The drug was even more effective when used in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).  [Read Article]

Study highlights limits of whole genome sequencing

HT Staff Read Article
Published: 04/04/12

genome.jpg
Genome gradient

A large study casts doubt on whether whole genome sequencing can reliably predict the risk of cancer and other diseases for most individuals. Researchers studied thousands of identical twins and found evidence to suggest that whole genome sequencing cannot accurately predict the risk of developing cancer in individuals without a family history of that cancer. In fact, those who undergo whole genome sequencing and receive a negative test result for a certain . . . [Read Article]

Protein plays role in leukemia/lymphoma transformation

HT Staff Read Article
Published: 04/03/12

lab_mouse_240.jpg
Lab mouse

Results of preclinical research suggest the mutation of a ribosomal protein is associated with the development of hematologic malignancies. The researchers found that germline inactivation of the ribosomal protein L22 predisposes T-lineage progenitors to leukemia and lymphoma transformation. David L. Wiest, PhD, of the Fox Chase Cancer Center in Philadelphia, and his colleagues presented this research April 2 at the AACR Annual Meeting 2012 as abstract 1353. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}